TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20299535
Drug: Sedation per
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation per usual care plus daily SBTs (control)
Study: 16080072
Drug: Tigecycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigecycline (100 mg followed by 50 mg intravenously twice daily)
Study: 16080072
Drug: Vancomycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (1 g intravenously twice daily) plus Aztreonam (2 g intravenously twice daily)
Study: 1922662
Drug: Alternate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate treatment with Prednisone (Polfa) and Decaris (Richter)
Study: 23099809
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy with 5‐FU/LEV
Study: 17653259
Drug: Prosaptide (PRO)
Normalized name: Climara Pro
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prosaptide (PRO) 8 mg/d
Study: 17653259
Drug: Prosaptide (PRO)
Normalized name: Climara Pro
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prosaptide (PRO) 16 mg/d
Study: 15277146
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g c9,t11 CLA/d
Study: 11023084
Drug: Pyrvinium pamoate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrvinium pamoate, 5 mg/kg/day for 3 days
Study: 1337525
Drug: Lomefloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin (400 mg orally once daily)
Study: 1337525
Drug: TMP/SMX (160/800
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP/SMX (160/800 mg orally twice daily)
Study: 22241602
Drug: Granisetron 40
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron 40 μg/kg
Study: 22241602
Drug: Granisetron 10
Normalized name: GRANISETRON 10MG/0.4ML INJ,SYRINGE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 10 μg/kg
Study: 22241602
Drug: Granisetron 10
Normalized name: GRANISETRON 10MG/0.4ML INJ,SYRINGE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 10 μg/kg and 40 μg/kg
Study: 15386762
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy for women with recently diagnosed primary breast cancer
Study: 9527733
Drug: Thiopentone induction
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone induction and isoflurane maintenance plus ondansetron 5 mg x m(‐2) i.v.
Study: 9527733
Drug: Propofol induction
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol induction and maintenance plus lignocaine 2 mg x kg(‐1) i.v.
Study: 7608323
Drug: Rivastatin 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastatin 300 micrograms once daily
Study: 194679
Drug: L phenylalanine
Normalized name: UNDECYLENOYL PHENYLALANINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L phenylalanine mustard (L PAM)
Study: 194679
Drug: L PAM
Normalized name: OXANTEL PAMOATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: L PAM
Study: 22154118
Drug: FEC-DH (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC-DH (4 cycles of FEC followed by 4 cycles of trastuzumab and 4 cycles of docetaxel 75 mg/m(2))
Study: 16305563
Drug: Misoprostol 400
Normalized name: Misoprostol 400 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 400 mcg/1.5 mL gel solution
Study: 12819295
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with epoetin beta (NeoRecormon) administered subcutaneously aiming for a target Hb level of 13‐15 g/dl.
Study: 12819295
Drug: Late treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late treatment with epoetin beta (NeoRecormon) administered subcutaneously starting once Hb level declines to below 10.5 g/dl (target Hb level 10.5‐11.5 g/dl).
Study: 1863026
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of bumetanide (12 mg over 12 hours)
Study: 1863026
Drug: Bolus therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus therapy of bumetanide (two 6 mg doses separated by 6 hours)
Study: 1863026
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of bumetanide
Study: 1863026
Drug: Bolus therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus therapy of bumetanide
Study: 6756931
Drug: Terbutaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline infusion during placebo
Study: 6756931
Drug: Terbutaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline infusion during acebutolol medication
Study: 3883878
Drug: Acebutolol 400
Normalized name: acebutolol 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol 400 mg
Study: 11899174
Drug: Cold crystalloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold crystalloid perfusion (4 degrees C Ringer's lactate solution)
Study: 9645457
Drug: Granisetron (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (0.5 mg i.v. bolus + continuous infusion of 0.04 mg/h for 7 days)
Study: 8174846
Drug: Vehicle (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (50 ml saline)
Study: 3237194
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion (3,680 mIU in 45 min)
Study: 23713245
Drug: Aspirin (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (Group B)
Study: 19114685
Drug: Control (bevacizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (bevacizumab and chemotherapy without panitumumab)
Study: 3300174
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion therapy (CSII)
Study: 29607554
Drug: Hydrocortisone butyrate
Normalized name: Hydrocortisone Butyrate
DrugBank: Hydrocortisone butyrate (DB14540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone butyrate ointment
Study: 15643131
Drug: Candesartan 8
Normalized name: candesartan 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8 mg daily for 16 weeks
Study: 15643131
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg daily for 16 weeks
Study: 11881123
Drug: Candesartan 16
Normalized name: candesartan 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 16 mg once-daily
Study: 7824108
Drug: 20% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% glucose infusion
Study: 8173308
Drug: 150% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150% of calculated daily calorie intake
Study: 26067435
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment mismatching the biomarker indication
Study: 12885805
Drug: Subcutaneous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous low-dose IFNalpha2b (3 million international units [MU]/m2/d, days 1 to 7, week 1; three times weekly, weeks 3 to 6, repeated all 6 weeks) plus IL-2 (9 MU/m2/d, days 1 to 4, week 2 of each cycle) for 48 weeks
Study: 12885805
Drug: Subcutaneous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous low-dose IFNalpha2b plus IL-2
Study: 1664869
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride (NaCl; placebo), dosage: 1.5 g total, 2.5 h prior to exercise
Study: 7208632
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of active head rotation toward the extending wrist and vibration of the extensor surface
Study: 26652904
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogens (oCEE)
Study: 18587579
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion etoposide
Study: 12458394
Drug: Insulin-stimulated myocardial
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-stimulated myocardial glucose uptake.
Study: 10362195
Drug: Carvedilol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (mean dosage 74±23 mg/day)
Study: 10362195
Drug: Metoprolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (mean dosage 142±44 mg/day)
Study: 7557850
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) alfa therapy
Study: 31136431
Drug: New oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New oral anticoagulants
Study: 24315724
Drug: New oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New oral anticoagulants (low-dose)
Study: 16263866
Drug: PTSD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTSD treatment for peacekeepers
Study: 16263866
Drug: PTSD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTSD treatment for Vietnam veterans
Study: 12198002
Drug: Iron bis-glycine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron bis-glycine chelate (encapsulated in enteric gelatin capsules)
Study: 30959472
Drug: Standard-of-care treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care treatment (control)
Study: 27105563
Drug: 2-dose adult
Normalized name: glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose adult formulation
Study: 27105563
Drug: 3-dose paediatric
Normalized name: glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose paediatric formulation
Study: 27105563
Drug: Challenge dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Challenge dose of monovalent vaccine
Study: 10763172
Drug: Xylometazoline-Dexpanthenol nasal
Normalized name: xylometazoline Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylometazoline-Dexpanthenol nasal spray
Study: 10763172
Drug: Xylometazoline nasal
Normalized name: xylometazoline nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylometazoline nasal spray
Study: 24596456
Drug: Tobramycin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin (80 mg/2 mL)
Study: 9886454
Drug: 1 microg
Normalized name: Alpha 1 microglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microg 1alpha(OH)D3 daily (treatment group, n=43)
Study: 9886454
Drug: 1 microg
Normalized name: Alpha 1 microglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 microg 1alpha(OH)D3 daily (treatment group)
Study: 10978944
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg loperamide
Study: 19159021
Drug: Tetracycline solution
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline solution (100 mg/mL) applied with a microbrush plus scaling and root planing (SRP+T)
Study: 19159021
Drug: Tetracycline solution
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline solution (100 mg/mL) applied with a microbrush (T)
Study: 16895678
Drug: Lifestyle measures
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle measures and pharmacological treatment of metabolic disorders
Study: 10982198
Drug: Sertraline (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50-100 mg)
Study: 9447852
Drug: BIS combined
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS combined with treatment history
Study: 2228324
Drug: Theophylline ethylenediamine
Normalized name: Theophylline ethylenediamine
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline ethylenediamine (2.5 mg/kg)
Study: 2228324
Drug: Theophylline ethylenediamine
Normalized name: Theophylline ethylenediamine
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline ethylenediamine (5.0 mg/kg)
Study: 2228324
Drug: Theophylline ethylenediamine
Normalized name: Theophylline ethylenediamine
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline ethylenediamine (7.5 mg/kg)
Study: 28044255
Drug: Mavoglurant (modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavoglurant (modified release) as augmentation therapy to SSRIs
Study: 26203098
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg oral iodine daily for 6 months
Study: 18972723
Drug: Elongated needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elongated needle therapy
Study: 14669965
Drug: PUFA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUFA supplementation (480 mg DHA, 80 mg EPA, 40 mg AA, 96 mg GLA, 24 mg alpha‐tocopheryl acetate)
Study: 8874562
Drug: Warmed intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed intravenous fluids
Study: 30229439
Drug: Propranolol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (2 mg/kg/day) administered during the neovascularization phase of ROP (stage 2)
Study: 30229439
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline solution (control group)
Study: 24309401
Drug: Metoprolol 50
Normalized name: metoprolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 50 mg once daily for 15 days
Study: 24309401
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no β‐blocker therapy)
Study: 20509074
Drug: Temporal sequence
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temporal sequence of suggestions (L followed by M)
Study: 12032037
Drug: Continuous psoas
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous psoas compartment block (CPCB) with 0.2% ropivacaine, initial loading dose of 0.4 mL/kg, followed by continuous infusion for 48 hours.
Study: 10221186
Drug: 1% preservative-free
Normalized name: lidocaine 1% preservative-free injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% preservative-free lidocaine intracameral injection
Study: 429218
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion with papaverin and dextran
Study: 27686182
Drug: Tdap vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap vaccine (0.5 mL IM)
Study: 12201616
Drug: Oxybutynin ER
Normalized name: Oxybutynin Chloride 5 MG Oral Tablet, Extended Release [OXYBUTYNIN ER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin ER 5 mg
Study: 12201616
Drug: Oxybutynin ER
Normalized name: Oxybutynin Chloride 5 MG Oral Tablet, Extended Release [OXYBUTYNIN ER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin ER 10 mg
Study: 479006
Drug: Indomethacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25 mg three times a day for three days preoperatively and three weeks postoperatively)
Study: 31156083
Drug: Extended course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended course (EC) prednisolone therapy: 60 mg/m2/day for weeks 1-4, tapering from 60 mg/m2 on alternate days for weeks 5-16 (total 3150 mg/m2)
Study: 31156083
Drug: Standard course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard course (SC) prednisolone therapy: 60 mg/m2/day for weeks 1-4, 40 mg/m2 on alternate days for weeks 5-8, and matching placebo for weeks 9-18 (total 2240 mg/m2)
Study: 31156083
Drug: Extended course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended course (EC) prednisolone therapy
Study: 29936923
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 μg/d as Se yeast)
Study: 25346332
Drug: Cold Infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold Infusions (CI) at 4°C, 2L at 4L/h
Study: 25346332
Drug: Cold Infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold Infusions (CI)
Study: 15705374
Drug: Oral L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-carnitine (2 g/day) for 3 months
Study: 12431966
Drug: TNP-470 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNP-470 at 60 mg/m² three times per week and paclitaxel at 225 mg/m² administered over 3 hours every 3 weeks
Study: 16454441
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 mg/d)
Study: 2206826
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg) and nifedipine retard (20 mg) once daily
Study: 12182261
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg once daily)
Study: 2206826
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of atenolol and nifedipine
Study: 113074
Drug: 2000 rad
Normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 rad in 8 fractions over 10 days with intravenous 5 Fluorouracil (5 F.U.) at a dose of 500 mg daily x 4 days preirradiation and then 12.5 mg/kg daily for 5 days every 28 days for six courses.
Study: 16892265
Drug: Red mixed
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red mixed berry juice (700 mL daily, TEAC: 19.1 mmol/L trolox)
Study: 16892265
Drug: Control juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control juice (polyphenol-depleted, TEAC: 2.4 mmol/L trolox)
Study: 9378844
Drug: YM90K (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: YM90K (36 mg single dose, 24 mg repeated dose over 3 hours)
Study: 9378844
Drug: YM90K (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: YM90K (24 mg repeated doses)
Study: 28931500
Drug: Web-based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based Cognitive Remediation Therapy (CogRem)
Study: 25742919
Drug: Tirasemtiv 250
Normalized name: Tirasemtiv
DrugBank: Tirasemtiv (DB12209)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirasemtiv 250 mg
Study: 11518200
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (25 g/d providing 7.5 g n-3 LCPUFAs)
Study: 11518200
Drug: High-oleic sunflower
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-oleic sunflower oil (25 g/d providing 22 g monounsaturated fatty acids)
Study: 9545673
Drug: Cefopzopran (CZOP)
Normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefopzopran (CZOP) 18.75 mg/kg
Study: 3731682
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg po q.i.d. for 2 weeks)
Study: 27652679
Drug: Paracetamol (taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (taken regularly or as needed)
Study: 24917631
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus osteopathic manipulative treatment (SC+OMT)
Study: 18445141
Drug: AGN 201904‐Z
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN 201904‐Z (600 mg/day)
Study: 18445141
Drug: Esomeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (40 mg/day)
Study: 11576031
Drug: QI-medications program
Approvals — FDA: no, EMA: no, PMDA: no
Description: QI-medications program
Study: 11576031
Drug: QI-therapy program
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: QI-therapy program
Study: 3581030
Drug: CHOP without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHOP without intermediate dose methotrexate
Study: 12823235
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (30 micro g/ml zinc)
Study: 11728289
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil 32 mg (with hydrochlorothiazide 12.5 mg if DBP was 90 mmHg or higher at week 8)
Study: 8840098
Drug: aprotinin (200,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: aprotinin (200,000 U.I.C. as intravenous bolus injection)
Study: 8840098
Drug: placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (10 ml isotonic saline)
Study: 1538302
Drug: Cimetidine 5
Normalized name: IBUPROFEN 2 g in 100 g / CIMETIDINE 5 g in 100 g / SALICYLIC ACID 17 g in 100 g TOPICAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 5 mg/kg
Study: 1538302
Drug: Cimetidine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 7.5 mg/kg
Study: 30753623
Drug: L-histidine injection
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-histidine injection
Study: 29193943
Drug: Local steroids
Normalized name: RECTAL,LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local steroids combined with therapeutic exercise at home
Study: 29193943
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (Control)
Study: 26427112
Drug: Standard DCXC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard DCXC therapy (2-g corbrin capsules, 3 times/d, 3 days before and after angiography)
Study: 26427112
Drug: Intensive DCXC
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive DCXC therapy (3-g corbrin capsules, 3 times/d, 3 days before and after angiography)
Study: 15742419
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment group
Study: 26427112
Drug: Standard DCXC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard DCXC therapy
Study: 26427112
Drug: Intensive DCXC
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive DCXC therapy
Study: 23123272
Drug: Carbohydrate-electrolyte solution
Normalized name: CARBOHYDRATE/ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-electrolyte solution (CES)